Black Diamond Therapeutics (BDTX) Non Operating Interest Expenses (2020)
Black Diamond Therapeutics' (BDTX) quarterly Non Operating Interest Expenses came in at $1000.0 in Q2 2020.
Powered by 
Analysis
Black Diamond Therapeutics (BDTX) Non Operating Interest Expenses (2020) Analysis & Trends
Black Diamond Therapeutics (BDTX) has reported Non Operating Interest Expenses for 1 consecutive years, with $1000.0 the latest figure, recorded in Q2 2020.
- For the quarter ending Q2 2020, Non Operating Interest Expenses changed N/A year-over-year to $1000.0; the trailing twelve-month figure through Sep 2021 stood at $1000.0 (changed 0.0% YoY), and the FY2020 full-year result was $1000.0, changed N/A from the prior year.
- Non Operating Interest Expenses held at $1000.0 in Q2 2020 per BDTX's latest filing.
- Across five years, Non Operating Interest Expenses topped out at $1000.0 in Q2 2020 and bottomed at $1000.0 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Black Diamond Therapeutics | 111.58 Mn | 1.07 Mn | - | - |